HeyJaredNick Paul Taylor
STORY ANGLES - Focuses on competitive dynamics: Highlights how companies position themselves against rivals (e.g., UCB vs. Gilead, Viridian vs. Amgen). - Emphasizes market impact: Covers funding trends, stock movements, and blockbuster potential of therapies.
- Indexed articles, last 90 days
- 14
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Fierce Biotech
- Top 500K sites
- Earliest in this view
- Sep 24, 2026
Latest articles
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 (opens the original)
Read excerpt
A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analysts, shares in Boehringer’s partner Zealand Pharma fell 12% in early trading in Denmark. The data, which researchers presented at the Annual Meeting of the European Association for the Study of Diabetes in Milan, come from the Synchronize-2 study. Investigators randomized 755 adults to receive weekly i
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D (opens the original)
Read excerpt
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success. Dupixent, an antibody that targets IL-4 and IL-13, generated 5.2 billion euros ($5.9 billion) for Sanofi in the second quarter and is the cornerstone of the French pharma's business. With the U.S. patent on the compound expiring in 2031—and Sanofi’s efforts to develop new growth drivers stuttering—the Paris-based drugmak
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program (opens the original)
Read excerpt
Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28. Roche, which in 2025 paid $1.65 billion upfront for petrelintide, and Zealand shared topline results from the Zupreme 1 trial in March and presented an expanded dataset in June. In those updates, the partners focused on the up to 10.7% mean weight loss seen at Week 42 of the trial without disclosing the Week 28 pri
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data (opens the original)
Read excerpt
Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body weight. Lilly reported topline data from the trial, Triumph-2, in July. The drugmaker shared a detailed look at the data on Tuesday at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and in The Lancet. This week’s update provides a fuller picture of how 1,152 adul
uniQure stock crashes as Huntington’s gene therapy data weaken (opens the original)
Read excerpt
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months, sending the biotech’s stock down 41% when trading began. But mitigating circumstances and the ongoing strength of a secondary endpoint kept analysts optimistic about AMT-130’s path to approval. One year ago, uniQure linked AMT-130 to a 75% slowing of disease progression, as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS), at Month 36 of a phase 1/2 trial.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Fierce Biotech, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.